Literature DB >> 22089883

Expression of transglutaminase-2 isoforms in normal human tissues and cancer cell lines: dysregulation of alternative splicing in cancer.

V M Phatak1, S M Croft, S G Rameshaiah Setty, A Scarpellini, D C Hughes, R Rees, S McArdle, E A M Verderio.   

Abstract

The multiple enzymatic activities and functions of transglutaminase type 2 (TG2) may be attributed to alternative TG2 molecules produced by differential splicing of TG2 mRNA. Different RNA transcripts of the human TG2 gene (TGM2) have been identified, but the expression of TG2 multiple transcripts has never been systematically addressed. We have confirmed and rationalized the main TG2 variants and developed a screening assay for the detection of alternative splicing of TG2, based on real-time reverse-transcription PCR. We have quantified the multiple TG2 transcripts in a wide range of normal tissues and in cancer cell lines from four different sites of origin. Our data show a significant correlation in the expression of canonical and alternative TG2 isoforms in normal human tissue, but differences in alternative splicing of TG2 in cancer cell lines, suggesting that in cancer cells the alternative splicing of TG2 is a more active process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089883     DOI: 10.1007/s00726-011-1127-4

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  8 in total

Review 1.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

2.  Transglutaminase 2 in cancer.

Authors:  Lei Huang; A-Man Xu; Wei Liu
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

3.  TGM2: a cell surface marker in esophageal adenocarcinomas.

Authors:  Deborah T Leicht; Tasneem Kausar; Zhuwen Wang; Daysha Ferrer-Torres; Thomas D Wang; Dafydd G Thomas; Jules Lin; Andrew C Chang; Lin Lin; David G Beer
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

4.  Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.

Authors:  Sara Zonca; Giulia Pinton; Zhuo Wang; Maria Felicia Soluri; Daniela Tavian; Martin Griffin; Daniele Sblattero; Laura Moro
Journal:  Cell Death Dis       Date:  2017-02-02       Impact factor: 8.469

Review 5.  The Role of Tissue Transglutaminase in Cancer Cell Initiation, Survival and Progression.

Authors:  Claudio Tabolacci; Angelo De Martino; Carlo Mischiati; Giordana Feriotto; Simone Beninati
Journal:  Med Sci (Basel)       Date:  2019-01-25

Review 6.  Spotlight on the Transglutaminase 2-Heparan Sulfate Interaction.

Authors:  Giulia Furini; Elisabetta A M Verderio
Journal:  Med Sci (Basel)       Date:  2019-01-04

7.  The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2.

Authors:  Nicoletta Bianchi; Federica Brugnoli; Silvia Grassilli; Karine Bourgeois; Jeffrey W Keillor; Carlo M Bergamini; Gianluca Aguiari; Stefano Volinia; Valeria Bertagnolo
Journal:  Cells       Date:  2021-11-06       Impact factor: 6.600

8.  Interplay between transglutaminases and heparan sulphate in progressive renal scarring.

Authors:  Izhar Burhan; Giulia Furini; Hugues Lortat-Jacob; Adeola G Atobatele; Alessandra Scarpellini; Nina Schroeder; John Atkinson; Mabrouka Maamra; Faith H Nutter; Philip Watson; Manlio Vinciguerra; Timothy S Johnson; Elisabetta A M Verderio
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.